Abstract | OBJECTIVE: METHODS: The Cilostazol: A Study in Long-Term Effects (CASTLE) trial was a prospective randomized double-blinded trial to establish the safety of this PDE3 inhibitor use in 1435 patients with mild to moderate peripheral arterial occlusive disease. A post hoc analysis of the CASTLE trial was undertaken to evaluate cilostazol use on cerebrovascular events. Blinded adjudication of all cerebrovascular events ( stroke, transient ischemic attack, and carotid revascularization) in this trial was performed. Kaplan-Meier analysis was used for statistical evaluation. RESULTS: The overall rate of cerebrovascular events was 4.6% (67 of 1435 patients) with a mean follow-up of 515 days. Ischemic vascular events were more common (2.5%) than hemorrhagic events (0.3%; P < .05). The placebo group demonstrated a greater risk for events (6.1%; 43 of 718 patients) versus the cilostazol treated group (3.2%; 24 of 717 patients; P < .05). Cerebrovascular risk factors were similar in both groups. CONCLUSION:
|
Authors | William M Stone, Bart M Demaerschalk, Richard J Fowl, Samuel R Money |
Journal | Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
(J Stroke Cerebrovasc Dis)
2008 May-Jun
Vol. 17
Issue 3
Pg. 129-33
ISSN: 1532-8511 [Electronic] United States |
PMID | 18436153
(Publication Type: Clinical Trial, Phase IV, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Cardiovascular Agents
- Phosphodiesterase 3 Inhibitors
- Phosphodiesterase Inhibitors
- Tetrazoles
- Cyclic Nucleotide Phosphodiesterases, Type 3
- Cilostazol
|
Topics |
- Aged
- Cardiovascular Agents
(pharmacology, therapeutic use)
- Cerebrovascular Disorders
(enzymology, etiology, prevention & control)
- Cilostazol
- Cyclic Nucleotide Phosphodiesterases, Type 3
(metabolism)
- Double-Blind Method
- Female
- Humans
- Intermittent Claudication
(drug therapy, enzymology, etiology)
- Male
- Middle Aged
- Peripheral Vascular Diseases
(complications, drug therapy, enzymology)
- Phosphodiesterase 3 Inhibitors
- Phosphodiesterase Inhibitors
(pharmacology, therapeutic use)
- Prospective Studies
- Risk Assessment
- Severity of Illness Index
- Tetrazoles
(pharmacology, therapeutic use)
- Time Factors
- Treatment Outcome
|